Core Viewpoint - The significant stock price surge of 精优药业 (00858.HK) is primarily driven by an announcement of expected profitability, although the underlying business fundamentals remain weak and the profit is largely attributed to non-operational factors [1][2]. Group 1: Stock Performance - On June 24, 精优药业 experienced a dramatic stock price increase, rising over 94% at one point and closing up 90.2% at HKD 0.097 per share, with a market capitalization of HKD 232 million [1]. - The trading volume for the day was notably high, reaching 267 million shares and a transaction value of HKD 25 million, resulting in a turnover rate of 12.44% [1]. Group 2: Financial Performance - The company announced an expected profit of between HKD 215 million and HKD 225 million for the fiscal year ending March 31, 2025, marking a turnaround from previous losses [1]. - However, the reported profit is primarily due to non-cash items related to fair value changes of convertible bonds, rather than improvements in core business operations [1][2]. - Historically, 精优药业 has struggled with weak revenue and fluctuating profitability from 2019 to 2024, often recording significant losses [1]. Group 3: Business Operations - 精优药业 operates mainly in the pharmaceutical product trading sector, with three divisions: manufacturing, trading, and gene development [2]. - The manufacturing division focuses on the development, production, and sales of pharmaceutical products, while the trading division promotes and distributes international products [2]. - The gene development division is involved in the commercial development and research of gene-related technologies [2]. Group 4: Market Sentiment - Market analysts suggest that the recent profit announcement does not indicate a fundamental improvement in the company's operations, and the sustainability of the stock price rebound remains uncertain [2].
精优药业暴涨90% 背后的尴尬：单日狂飙难改“仙股”宿命